Bombesin-Targeted PET of Prostate Cancer.
Imaging plays an important role in prostate cancer (PC), including accurate evaluation of the extent of disease, assessment of sites of recurrent disease, and monitoring of response to treatment. Molecular imaging techniques are among the novel developments related to the imaging of PC, and various SPECT and PET radiopharmaceuticals are now available in clinical trials or commercially. Here we describe the preclinical and clinical use of gastrin-releasing peptide receptors as targets for the imaging of PC, with a focus on the development of PET tracers for the imaging of gastrin-releasing peptide receptor-positive tumors.
Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, Germany.
Rosalba
R
Mansi
Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan; and.
Ryogo
R
Minamimoto
Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, Germany.
Helmut
H
Mäcke
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California aiagaru@stanford.edu.
Andrei H
AH
Iagaru
D014408:Biomarkers, Tumor / Q000378:metabolism; D001839:Bombesin / Q000493:pharmacokinetics*; D019317:Evidence-Based Medicine; D006801:Humans; D007089:Image Enhancement; D008297:Male; D057054:Molecular Imaging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D018004:Receptors, Bombesin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D018004:Receptors, Bombesin; D001839:Bombesin
PET; bombesin; cancer; prostate